Transgene presented promising preclinical data on its novel oncolytic virus TG6050, at the American Association for Cancer Research (AACR) Annual Meeting, April 14-19, 2023. These data demonstrate the ability of TG6050 to induce strong antitumor responses through the production of IL-12 and anti-CTLA4 antibody in the tumor and the induction of innate and adaptive immune responses. TG6050 is a clinical-stage oncolytic virus that has been engineered to encode human IL-12 and a full length anti-CTLA4 antibody.

It is derived from the Invir.IO platform and its patented VVCOPTK-RR- viral vector which was shown to be well tolerated in humans and to replicate and express payloads in tumor tissues. Key results of the poster are as follows: Sustained expression of IL-12 has been detected in tumors after intravenous and intratumoral administration of the murine version of TG6050 (mTG6050). The levels of functional IL-12 found in the tumor reach active concentrations.

They are associated with low systemic exposure. mTG6050 treatment increased T cell responses capable of killing cancer cells. Transcriptomic and immunological analyses clearly show a remodeling of the tumor micro-environment and the activation of numerous innate and adaptive immune pathways.

In several mice models, mTG6050 displayed a very strong anti-tumor activity.